HPV16-E7-T512
Biologicalexperimental
Clinical trial activity
13 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
11
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01146197)
Timeline
Indications
Studied for
- Anus Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Cervical Intraepithelial Neoplasia · Phase 2
- Gitelman Syndrome · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 2
- Lung Neoplasms · Phase 3
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1/Phase 2
- Oropharyngeal Neoplasms · Phase 1
- Rectal Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Uterine Cervical Neoplasms · Phase 3
- Vitamin D Deficiency · Phase 2
Mechanism of action
- Human papillomavirusINHIBITOR
Human papillomavirus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- adxs11-001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03226470 | Phase 1 | Jan 10, 2018 | Huazhong University of Science and Technology |
| NCT02531854 | Phase 2 | Dec 1, 2016 | Advaxis, Inc. |
| NCT02613884 | Phase 2 | Nov 1, 2016 | Johns Hopkins University |
| NCT02853604 | Phase 3 | Sep 1, 2016 | Advaxis, Inc., Gynecologic Oncology Group, Sylvester Comprehensive Cancer Center, University of Cincinnati |
| NCT02399813 | Phase 2 | Sep 1, 2015 | Advaxis, Inc. |
| NCT02291055 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | Advaxis, Inc., MedImmune |
| NCT02164461 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Advaxis, Inc. |
| NCT02002182 | Phase 2 | Dec 1, 2013 | Advaxis, Inc., Baylor University, Icahn School of Medicine at Mount Sinai |
| NCT01671488 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2013 | Brown University, Rhode Island Hospital |
| NCT01598792 | Phase 1 | Feb 1, 2012 | Advaxis, Inc., Cancer Research UK, Recipharm, University of Liverpool |
| NCT01154140 | Phase 3 | Jan 13, 2011 | Pfizer |
| NCT01116245 | Phase 2 | Apr 1, 2010 | Advaxis, Inc. |
| NCT01146197 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2010 | University of Paris |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advaxis, Inc. | For profit | 8 | 6 | 3 | 2010 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Brown University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| MedImmune | For profit | 1 | 0 | 1 | 2015 |
| Pfizer | For profit | 1 | 1 | 1 | 2011 |
| Recipharm | For profit | 1 | 0 | 1 | 2012 |
| Rhode Island Hospital | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Sylvester Comprehensive Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Liverpool | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Paris | Academic/Hospital | 1 | 1 | 1 | 2010 |
16 organizations
Page 1 / 1